FDAapproval72% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to AstraZeneca.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Supporting Context
- Therapeutic area
- Oncology · PARP Inhibitor
- Sub-indication
- General
Related signal: AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea